

8	Exceptional items	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (7 - 8)	3,191.96	2,562.13	1,555.68	7,781.52
10	Tax Expenses	578.95	332.54	316.42	1,467.84
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	2,613.01	2,229.59	1,239.26	6,313.68
12	Extraordinary Items (net of tax expenses Rs.....Lacs)	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	2,613.01	2,229.59	1,239.26	6,313.68
14	Share of Profit / (Loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	2,613.01	2,229.59	1,239.26	6,313.68
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,393.39	1,393.39	1,016.40	1,393.39
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-
19	Earnings per Share (before Extraordinary Itemsz(of Rs.10/- each))(not annualised)	-	-	-	-
	(a) Basic	18.75	16.00	12.19	45.31
	(b) Diluted	12.66	15.76	10.24	39.31

1. The above Consolidated Unaudited Financial Results for the Quarter ended June 30, 2012 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on August 13, 2012.

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sehen Private Limited, (iv) Octtantis Nobel Labs Private Limited, (v) Vivimed Holdings Limited and its step down subsidiaries viz. (i) Vivimed Labs Europe Limited (ii) Vivimed Labs Mauritius Limited (iii) Vivimed Labs UK Limited, (iv) Vivimed Labs Spain, S.L. (v) Union Quimico Farmaceutica S.A., Spain, (vi) Uquifa Mexico S.A. de C.V. & (vii) Holiday International Limited, UK.

3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH VARAIWAR)
MANAGING DIRECTOR & CEO

Place : Hyderabad

Date : 13/08/2012